Tempest Therapeutics Faces Nasdaq Noncompliance, Plans Annual Meeting

Tempest Therapeutics ( (TPST) ) has shared an update.

Tempest Therapeutics disclosed that on January 8, 2026 it received a notice from Nasdaq’s Listing Qualifications Department stating the company was not in compliance with Nasdaq’s continued listing rules because it failed to hold an annual shareholders’ meeting within twelve months of its December 31, 2024 fiscal year end. The company has already scheduled its 2025 Annual Meeting of Stockholders for January 27, 2026, and under Nasdaq rules it has until February 23, 2026 to regain compliance or submit a remediation plan, with a potential extension to June 29, 2026; holding the January 27 meeting is expected to restore compliance and reduce the near-term risk to its Nasdaq listing status for shareholders.

The most recent analyst rating on (TPST) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.

Spark’s Take on TPST Stock

According to Spark, TipRanks’ AI Analyst, TPST is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, sizable ongoing losses, heavy cash burn, and a materially reduced equity/asset base). Technicals also weigh negatively due to a strong downtrend, with only modest offset from oversold signals. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.

To see Spark’s full report on TPST stock, click here.

More about Tempest Therapeutics

Tempest Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics, and its shares are listed on The Nasdaq Stock Market LLC.

Average Trading Volume: 118,241

Technical Sentiment Signal: Sell

Current Market Cap: $13.85M

Find detailed analytics on TPST stock on TipRanks’ Stock Analysis page.